<DOC>
	<DOCNO>NCT00019916</DOCNO>
	<brief_summary>RATIONALE : Vaccines may make body build immune response kill tumor cell . Interleukin-2 may stimulate person 's white blood cell kill tumor cell . It yet know whether combine vaccine therapy interleukin-2 effective treating breast ovarian cancer . PURPOSE : This randomized phase I/II trial study side effect vaccine therapy interleukin-2 see well work treat woman stage IV , recurrent , progressive breast ovarian cancer .</brief_summary>
	<brief_title>Vaccine Therapy Plus Interleukin-2 Treating Women With Stage IV , Recurrent , Progressive Breast Ovarian Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine whether endogenous cellular immunity p53 peptide vaccine present patient stage IV , recurrent , progressive breast ovarian cancer whether vaccination peptide low-dose interleukin-2 induce boost cellular immunity patient . - Determine type characteristic cellular immunity generate regimen patient . - Determine toxicity regimen patient . - Correlate immunologic response objective tumor response regimen patient . OUTLINE : This randomize , pilot study . Patients randomize 1 2 treatment arm . All patient undergo apheresis autologous peripheral blood mononuclear cell , harvest select monocyte day -6 . The monocyte fraction culture sargramostim ( GM-CSF ) interleukin-4 7 day pulse p53 peptide vaccine . - Arm I : Patients receive p53 peptide vaccine subcutaneously ( SC ) day 1 . - Arm II : Patients receive p53 peptide vaccine IV 5 minute day 1 . Treatment arm repeat every 3 week total 4 vaccination ( 4 course ) . During course 3 4 , patient also receive low-dose interleukin-2 ( IL-2 ) SC daily day 3-7 day 10-14 . Patients stable respond disease may continue receive vaccine IL-2 treatment 2 year . Patients follow 1 month every 2-4 month 2 year . PROJECTED ACCRUAL : A maximum 34 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven adenocarcinoma breast ovary Stage IV , recurrent , progressive disease chemotherapy radiotherapy option available would increase survival Tumor tissue available determination p53 protein expression genetic mutation p53positive tumor immunohistochemical analysis HLAA2.1 positive No prior CNS metastases Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Sex : Female Menopausal status : Not specify Performance status : ECOG 0 1 Life expectancy : More 3 month Hematopoietic : Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 2.0 mg/dL SGOT SGPT great 4 time normal Hepatitis B surface antigen negative Hepatitis C antibody negative Renal : Creatinine great 2.0 mg/dL Cardiovascular : No New York Heart Association class III IV heart disease No myocardial infarction within past 6 month No prior congestive heart failure No prior ventricular arrhythmia arrhythmia require therapy Immunologic : Must positive intradermal delay hypersensitivity test 1 following : Mumps Trichophyton Tetanus Candida PPD No underlie immune deficiency No prior autoimmune disease include , limited , follow : Autoimmune neutropenia , thrombocytopenia , hemolytic anemia Systemic lupus erythematosus , Sj√∂gren 's syndrome , scleroderma Myasthenia gravis Goodpasture 's syndrome Addison 's disease Hashimoto 's thyroiditis Active Graves ' disease No active infection require antibiotic HIV negative Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No active malignancy within past 2 year except curatively treat carcinoma situ cervix basal cell skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior immunotherapy recover At least 1 year since prior bone marrow transplantation Chemotherapy : At least 4 week since prior chemotherapy recover Endocrine therapy : Prior anticancer hormonal therapy allow At least 4 week since prior systemic steroid recover Radiotherapy : At least 4 week since prior radiotherapy recover Surgery : Not specify Other : Chronic suppressive antibiotic allow</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2005</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
</DOC>